Bendamustine: A novel cytotoxic agent for hematologic malignancies

Clinical Journal of Oncology Nursing

Volumn 12, Issue 5, 2008, Pages 799-806

  Blumel, Susan ^a   Goodrich, Amy ^b   Martin, Cheryl ^c   Dang, Nam H ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CHLORMETHINE DERIVATIVE;

ARTICLE; BLOOD DISEASE; CLINICAL TRIAL; HUMAN; NURSING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; NITROGEN MUSTARD COMPOUNDS;

EID: 58149280526     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.799-806     Document Type: Article

References (48)

1. Aivado, M., Schulte, K., Henze, L., Burger, J., Finke, J., & Haas, R. (2002). Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives. Seminars in Oncology, 29 (4, Suppl. 3), 19-22.
2. Anger, G., Hesse, P., & Baufeld, H. (1969). Treatment of multiple myeloma with a new cytostatic agent: Gamma-1-methyl-5-bis- (beta-chlorethyl) -amino-benzimidazolyl (2) -butyric acid hydrochloride. Deutsche Medizinische Wochenschrift, 94(48), 2495-2500.
3. Ansell, S.M., & Armitage, J. (2005). Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clinic Proceedings, 80(8), 1087-1097.
4. Bergmann, M.A., Goebeler, M.E., Herold, M., Emmerich, B., Wilhelm, M., Ruelfs, C., et al. (2005). Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica, 90(10), 1357-1364.
5. Bremer, K. (2002). High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. Journal of Cancer Research and Clinical Oncology, 128(11), 603-609.
6. Cephalon, Inc. (2008). Treanda (bendamustine hydrochloride) for injection [Package insert]. Frazer, PA: Author.
7. Cheson, B.D. (2004). What is new in lymphoma? CA: A Cancer Journal for Clinicians, 54(5), 260-272.
8. Chiorazzi, N., Rai, K.R., & Ferrarini, M. (2005). Chronic lymphocytic leukemia. New England Journal of Medicine, 352(8), 804-815.
9. Chow, K.U., Boehrer, S., Geduldig, K., Krapohl, A., Hoelzer, D., Mitrou, P.S., et al. (2001). In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica, 86(5), 485-493.
10. Davies, A.J. (2007). Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene, 26(25), 3614-3628.
11. Eichbaum, M.H., Schuetz, F., Khbeis, T., Lauschner, I., Foerster, F., Sohn, C., et al. (2007). Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: Final results of a phase II study. Anti-Cancer Drugs, 18(8), 963-968.
12. Friedberg, J.W. (2004). Radioimmunotherapy for non-Hodgkin's lymphoma. Clinical Cancer Research, 10(23), 7789-7791.
13. Friedberg, J.W., Cohen, P., Chen, L., Robinson, K.S., Forero-Torres, A., La Casce, A.S., et al. (2008). Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. Journal of Clinical Oncology, 26(2), 204-210.
14. Hallek, M. (2005). Chronic lymphocytic leukemia (CLL): First-line treatment. Hematology, 285-291.
15. Hasse, D., Priess, R., & Sohr, R. (1990). Untersuchungen zur plasmaciweibindung von bendamustin (Cytostasan) and Ambazon. Zeitschrift für klinische Medizin, 45, 1267-1272.
16. Heider, A., & Niederle, N. (2001). Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anti-Cancer Drugs, 12(9), 725-729.
17. Herold, M., Schulze, A., Niederwieser, D., Franke, A., Fricke, H.J., Richter, P., et al. (2006). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO# 19). Journal of Cancer Research and Clinical Oncology, 132(2), 105-112.
18. Hoffken, K., Merkle, K., Schonfelder, M., Anger, G., Brandtner, M., Ridwelski, K., et al. (1998). Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II study. Journal of Cancer Research and Clinical Oncology, 124(11), 627-632.
19. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58(2), 71-96.
20. Kahl, B.S., Bartlett, N., Leonard, J., Ganjoo, K., Williams, M., Czuczman, M., et al. (2007, December). Bendamustine is safe and effective in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma. Paper presented at the 49th Annual Meeting of the American Society of Hematology, Atlanta, GA.
21. Kanekal, S., Crain, B., & Elliott, G. (2004). SDX-105 (Treanda) enhances the tumor growth inhibitory effect of rituximab in Daudi lymphoma xenografts [Abstract]. ASH Annual Meeting Abstracts, 104, 4580.
22. Kath, R., Blumenstengel, K., Fricke, H.J., & Hoffken, K. (2001). Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. Journal of Cancer Research and Clinical Oncology, 127(1), 48-54.
23. Knauf, W., Lissitchkov, T., Aldoud, A., Herbrecht, R., Liberati, A., Loscertales, J., et al. (2007, December). Bendamustine versus chlorambucil in treatment-naïve patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an international Phase III study. Paper presented at the 49th Annual Meeting of the American Society of Hematology, Atlanta, GA.
24. Knop, S., Straka, C., Haen, M., Schwedes, R., Hebart, H., & Einsele, H. (2005). The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica, 90(9), 1287-1288.
25. Konstantinov, S.M., Kostovski, A., Topashka-Ancheva, M., Genova, M., & Berger, M.R. (2002). Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. Journal of Cancer Research and Clinical Oncology, 128(5), 271-278.
26. Koppler, H., Heymanns, J., Pandorf, A., & Weide, R. (2004). Bendamustine plus mitoxantrone-A new effective treatment for advanced chronic lymphocytic leukaemia: Results of a phase I/II study. Leukemia and Lymphoma, 45(5), 911-913.
27. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., et al. (2003). Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78(1), 21-33.
28. Leoni, L.M., Bailey, B., Niemeyer, C.C., Reifert, J., Bendall, H., Dauffenbach, L., et al. (2004). In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells [Abstract]. Proceedings of the American Association for Cancer Research Meeting, 45, 1215.
29. Leoni, L.M., Bailey, B., Reifert, J., Bendall, H.H., Zeller, R.W., Corbeil, J., et al. (2008). Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research, 14(1), 309-317.
30. Lissitchkov, T., Arnaudov, G., Peytchev, D., & Merkle, K. (2006). Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. Journal of Cancer Research and Clinical Oncology, 132(2), 99-104.
31. National Cancer Institute. (2006). Common terminology criteria for adverse events [v.3.0]. Retrieved January 8, 2008, from http://ctep.cancer.gov/forms/CTCAEv3.pdf
32. National Comprehensive Cancer Network. (2008a). Clinical Practice Guidelines in OncologyTM: Multiple myeloma. [v.1.2008]. Retrieved May 15, 2008, from http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf
33. National Comprehensive Cancer Network. (2008b). Clinical Practice Guidelines in OncologyTM: Non-Hodgkin's lymphoma. v.3.2008. Retrieved January 8, 2008, from http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf
34. Niemeyer, C., Bendall, H., Bailey, B., Reifert, J., & Leoni, L.M. (2005). Mitotic catastrophe induced in cells treated with SDX-105 (Treanda) [Abstract]. Proceedings of the American Association for Cancer Research, 46, 2291.
35. Owen, J.S., Melhem, M., D'Andrea, D., & Darwish, M. (2008). Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin's lymphoma (NHL). Pharmacology and Therapeutics, 83(Suppl. 1), S54.
36. Ponisch, W., Mitrou, P.S., Merkle, K., Herold, M., Assmann, M., Wilhelm, G., et al. (2006). Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-A randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical Oncology, 132(4), 205-212.
37. Rahn, A.N., Schilcher, R.B., Adamietz, I.A., Mose, S., Bormeth, S.B., & Bottcher, H.D. (2001). Palliative radiochemotherapy with bendamustine for advanced recurrent head and neck tumors. Strahlentherapie und Onkologie, 177(4), 189-194.
38. Robinson, K.S., Williams, M.E., van der Jagt, R.H., Cohen, P., Herst, J.A., Tulpule, A., et al. (2008). Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma [Electronic version]. Journal of Clinical Oncology. Retrieved September 15, 2008, from http://jco.ascopubs.org/cgi/content/abstract/JCO.2008.17.0001v1
39. Rummel, M.J., Chow, K.U., Hoelzer, D., Mitrou, P.S., & Weidmann, E. (2002). In vitro studies with bendamustine: Enhanced activity in combination with rituximab. Seminars in Oncology, 29(4, Suppl. 13), 12-14.
40. Rummel, M.J., von Grunhagen, U., Niederle, N., Rothmann, F., Ballo, H., Weidmann, E., et al. (2007). Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas-First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [Abstract]. Blood, 110, 385.
41. Schilcher, R.B., Zeller, S., Haase, C.G., & Rahn, A.N. (2001). Gemcitabine in intensively pretreated ENT tumors with pulmonary metastases [Abstract]. Proceedings of the American Society of Clinical Oncology, 20, 2552.
42. Schmittel, A., Knodler, M., Hortig, P., Schulze, K., Thiel, E., & Keilholz, U. (2007). Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer, 55(1), 109-113.
43. Schwanen, C., Hecker, T., Hubinger, G., Wolfle, M., Rittgen, W., Bergmann, L., et al. (2002). In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia, 16(10), 2096-2105.
44. Staib, P., Schinkothe, T., & Dimski, T. (2007). In vitro modulation of Ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2CdA and gemcitabine. Blood, 94, 63a.
45. Strumberg, D., Harstrick, A., Doll, K., Hoffmann, B., & Seeber, S. (1996). Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-Cancer Drugs, 7(4), 415-421.
46. Teichert, J., Baumann, F., Chao, Q., Franklin, C., Bailey, B., Hennig, L., et al. (2007). Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemotherapy and Pharmacology, 59(6), 759-770.
47. von Minckwitz, G., Chernozemsky, I., Sirakova, L., Chilingirov, P., Souchon, R., Marschner, N., et al. (2005). Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anti-Cancer Drugs, 16(8), 871-877.
48. Weidmann, E., Kim, S.Z., Rost, A., Schuppert, H., Seipelt, G., Hoelzer, D., et al. (2002). Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Annals of Oncology, 13(8), 1285-1289.